Laboratory Corporation of America Holdings LH · USD
Health Care · Health Care Providers & Services · US listing · 🇺🇸 United States
S&P 500
371.83
+1.43%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Laboratory Corporation of America Holdings
From its filings with the US Securities and Exchange Commission
Laboratory Corporation of America Holdings is based in Burlington, North Carolina. Its shares trade on NYSE under the ticker LH. It is a member of the S&P 500. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $13.95bn and net income of $876.5m. At that date it held total assets of $18.39bn and shareholders' equity of $8.62bn.
Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 85% of the new drugs and therapeutic products approved in 2025 by the FDA.
The Company’s strength in science, technology, and innovation, as well as its global scale, powers its continued success, differentiates the Company, and enables it to play a leading role in advancing healthcare across the globe. These strengths are critical to the Company’s ability to carry out its mission to improve health and improve lives.
Through leadership in science, technology and innovation, the Company provides vital information and services to help its customers make clear and confident decisions to improve health and improve lives.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 24 Apr 1991
- Employees
- 71,000
- Website
- labcorp.com ↗
- Head office
- 358 S MAIN ST, BURLINGTON, NC, 27215
- Classification
- Services-Medical Laboratories
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Adam SchechterChairman of the Board, President, Chief Executive Officer, since 2013$14.9m
- Mr. Glenn EisenbergChief Financial Officer, Executive Vice President$8.7m
- Mr. Thomas PikePresident, Chief Executive Officer - Clinical Development Business Unit
- Mr. Mark SchroederExecutive Vice President, President Diagnostics and Chief Operations Officer$2.8m
- Ms. Judith SeltzChief Human Resource Officer, Executive Vice President
- Mr. Lance BerberianExecutive Vice President, Chief Information and Technology Officer$2.7m
- Ms. Amy SummyExecutive Vice President, Chief Marketing Officer
- Dr. Brian CaveneyExecutive Vice President, President Early Development and Chief Medical and Scientific Officer$3.0m
- Ms. Sandra van Der VaartExecutive Vice President, Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
- Mr. Peter WilkinsonSenior Vice President, Chief Accounting Officer
- Mr. Peter NeupertLead Independent Director$384,985
- Ms. Kerrii AndersonIndependent Director$344,985
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 99
- Social
- 98
- Governance
- 58
- Direct emissions (scope 1)
- 182,265 t
- Energy emissions (scope 2)
- 155,929 t
- Value chain emissions (scope 3)
- 1,050,378 t
- Women in the workforce
- 70%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Laboratory Corporation of America Holdings (LabCorp) has a strong brand reputation in the healthcare industry as a leading provider of clinical laboratory services.
- LabCorp has a wide network of laboratories and facilities, allowing for efficient and timely delivery of services to customers across the United States.
- The company has a diverse portfolio of testing services and diagnostic solutions, offering a comprehensive range of medical testing options to healthcare providers and patients.
- LabCorp benefits from strategic partnerships and collaborations with pharmaceutical companies, healthcare providers, and research institutions, enhancing its market presence and facilitating innovation.
Weaknesses
- LabCorp faces intense competition from other prominent laboratory service providers, which may impact its market share and pricing power.
- The company heavily relies on third-party payers, such as insurance companies and government healthcare programs, for a significant portion of its revenue. Any changes in reimbursement policies or reduced payment rates could negatively affect LabCorp's financial performance.
- LabCorp's dependence on advanced technology and laboratory equipment makes it vulnerable to disruptions in supply chains or the introduction of more efficient technologies by competitors.
Opportunities
- The growing demand for personalized medicine and genetic testing presents opportunities for LabCorp to expand its portfolio of services and capture a larger market share.
- Expansion into international markets can provide LabCorp with access to new customer segments and revenue streams.
- Technological advancements, such as digital health platforms and telemedicine, offer LabCorp the chance to enhance its service delivery and improve patient experience.
Threats
- Regulatory changes and compliance requirements in the healthcare industry can pose challenges and increase operating costs for LabCorp.
- The ongoing COVID-19 pandemic has disrupted healthcare systems worldwide, leading to potential lower demand for non-essential testing services.
- Competitors' consolidation or entry into LabCorp's key markets may intensify competition and put pressure on the company's market position and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.